In this Healio Video Perspective from the Retina World Congress, Ashish Sharma, MBBS, MS, gives an update on aflibercept ...

Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

The U.S.-based NEW DAY clinical trial enrolled 306 patients with diabetic macular edema who received a single Iluvien ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

In both trials, patients treated with aflibercept 8 mg (PULSAR n=673; PHOTON n=491) met the primary endpoint of non-inferiority in vision gains for both the 12- and 16-week dosing regimens after ...

Vabysmo reduced retinal fluid from baseline compared to aflibercept, as measured by reduction in central subfield thickness (CST). At 12 weeks, CST reductions were 145 µm in the Vabysmo arm and ...

Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, and placental growth factor.

Intravitreal injections of aflibercept every 4 weeks after monthly injections may provide an additional benefit to patients with early persistent fluid from neovascular age-related macular ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of aflibercept, having considered evidence on the nature of macular oedema secondary to central retinal vein ...

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.